patients, it is disconcerting for the study design, because 75 to 100 prostate cancer deaths were expected to occur. This deficit in mortality is likely due to the yearly PSa testing which 85% of study subjects sought on their own-PSa testing was not a part of the study protocol. In most observational studies of this size, both early stage and advanced cancers would typically have been diagnosed. However, the degree of vigilance of this group of men, who elected to use intensive PSa testing outside of the study, meant that early stage cancers were virtually the only type diagnosed. If a variety of cancer stages had been diagnosed, we would have gained information from this trial on how the supplements might have affected occurrence of different stages of prostate cancer, which would have been quite interesting and made the assessment of supplement impact relevant. a number of points should be made about this study. First, SeLeCT and the other antioxidant supplement intervention trials that have recently been reported are many things, but they are definitely not integrative medicine. Nor are they complementary or alternative medicine. These large-scale antioxidant supplement trials are a product of the nutrition research community, which took the correlation of phytochemicals such as β-carotene with reduced cancer risk as an indication that single phytochemicals themselves were responsible for risk reduction, and used a pharma-style approach to studying nutrients as single-agent interventions. The extracted phytochemicals were first isolated and then given as pills in an effort to find an easy method for reducing cancer risks. easy reduction of cancer risk is certainly a worthy goal-but is it what traditional Chinese medicine recommends for reducing cancer risk? Or macrobiotics? Or ayurveda? Or Western herbalism? Or naturopathy? Of course not, and I do not know a single integrative clinician worthy of the name who would suggest to a patient concerned with cancer risk that he or she simply take 400 IU vitamin e daily to address the problem-especially using α-tocopherol, as opposed to mixed tocopherols. Sophisticated practitioners of integrative, traditional, and alternative medicine all frame risk reduction with multitargeted interventions, including overall dietary adjustment and exercise. To the extent that vitamins or antioxidant supplements are used, one would expect that these would be typically given in complex formulas of multiple phytochemicals and other compounds that are D ecember 2008 saw the online release of 2 major randomized studies of the cancer chemopreventive effects of antioxidant supplements in JaMa (now in print, January 7, 2009 issue of JaMa). The longawaited SeLeCT trial and the Physicians Health Study (PHS) II both examined the use of supplements in prostate cancer prevention, as well as total cancer prevention. 1, 2 Vitamin e was combined with selenium in the SeLeCT trial and with vitamin C in the PHS trial. Repeating the pattern of other recently published antioxidant trials, neither trial found that the single or combined antioxidant supplements succeeded in preventing either prostate or other cancers. This has caused the now-usual chorus of condemnations of everything from vitamin e to antioxidants to supplements in general to integrative, complementary, and alternative medicine as a whole in the popular press. There are several aspects of the SeLeCT trial in particular, in addition to findings of the PHS study, which we feel are worth comment. The SeLeCT trial, including more than 35,000 healthy subjects with prostate-specific antigen (PSa) levels <4 ng/mL, is the largest chemoprevention trial ever accomplished, and was well designed and well executed. after a rapid enrollment period, the trial ran for 7 years until its data and safety monitoring board halted it in 2008 when it became obvious that the hypothesized 25% difference in prostate cancer occurrence was not going to be reached. This study included 4 groups: placebo, vitamin e only (as α-tocopherol), selenium only (as selenomethionine), and selenium plus vitamin e. No significant difference in prostate cancer diagnoses was found between the 4 groups. There was, in fact, a nonsignificant increase in prostate cancer in the vitamin e only group (hazard ratio = 1.13, P = .06). No differences in other cancers were observed, and no difference in mortality was found. The only other possible safety concern was a nonsignificantly increased number of cases of type 2 diabetes in the selenium group. Interestingly, the great majority of prostate cancer cases that were diagnosed in this trial were very early stage. as pointed out in an accompanying editorial, 3 of the 1758 prostate cancers diagnosed in the study, only 10 extended beyond the prostate capsule, 1 had positive regional nodes and 9 were metastatic. Happily, there was only 1 prostate cancer death among the study subjects in this period. although this is an excellent outcome for these Articles Antioxidants: SELECTed out?
closer to the way these substances occur in nature-from foods, as extracts from whole plants. It certainly would have been laudable if integrative and complementary and alternative medicine (CaM) practitioners could have incorporated positive evidence of cancer risk reduction from large randomized trials using isolated single antioxidant supplements into their practice-but such positive evidence is clearly not going to be forthcoming. The negative trials of antioxidant supplements are thus not at all a commentary on the usefulness of CaM or integrative medicine (despite the participation of NCCaM in their funding), let alone the usefulness of supplements in general. In fact, an extraordinary number of studies where combination and whole plant supplements have been used, as in an augmented healthy whole food dietary plan, improvements in a number of cancer-related variables have been seen. a small but relevant recent example is a study where a multiherb supplement based on whole plant extracts demonstrated a marked decrease in expected conversion of the high-risk condition of high-grade prostatic intraepithelial neoplasia (hgPIN) to prostate cancer. Conversion of the neoplastic condition back to normal was seen in more than 50% of cases, where only 22% would have been expected to convert from historical data. 4 So if the impetus to examine single or simple combinations of antioxidant supplements did not come from CaM, exactly where did it come from? In the case of the SeLeCT trial, the hypothesis that selenium and vitamin e could prevent prostate cancer arose from subgroup analyses of the National Prevention of Cancer trial and the alpha-Tocopherol Beta-Carotene (aTBC) trials. although the primary goals of these trials were not prevention of prostate cancer, these secondary analyses showed that selenium and vitamin e appeared to protect against prostate cancer. The subgroup results were taken as a primary and solid justification for this very large-scale trial. Usually clinical hypotheses about natural products arise from observational, epidemiological studies or traditional healing uses, followed by laboratory and animal studies to firmly establish mechanisms and dosages. This procedure can then lead to phases I, II, and III clinical trials based on a thorough working knowledge of the substance (of course, this does not guarantee the trials will give positive results). The SeLeCT trial in a sense worked backwards from clinical trial results to a comparatively brief period of laboratory and animal studies, and then on to the very large randomized trial. The failure of the SeLeCT trial to find positive chemopreventive results may caution us against departing too far from the established pathways of natural products research. a reassuring finding of both the SeLeCT and the PHS trials was the lack of indication that any of the supplements significantly increased mortality or cancer rates. Vitamin e in particular has been regarded as potentially harmful based on results of some previous trials and meta-analyses. These meta-analyses were reviewed in 2008 by Bell and grochoski, 5 who point out several problems with the interpretation of the studies included. Meta-analysis results, they argue, can be distorted by selection of heterogeneous studies, that is, unmatched populations and treatments, differing study protocols, differing age groups, and inadequate interpretations of the studies that are selected. These authors analyzed the studies included in 3 meta-analyses of vitamin e that indicated possible harm from vitamin e supplements. The studies that appeared to affect the meta-analysis results most strongly had deficiencies that raise questions about the soundness of the meta-analytic conclusions. Most frequently, these were situations in with vitamin e was given along with another supplement, usually β-carotene, which has been shown to shift to pro-oxidant effects in an oxidatively stressed environment. The negative effects on mortality could actually have been from the other supplement in the combination, rather than vitamin e itself. The results of the SeLeCT and PHS studies add to our confidence in the safety of vitamin e.
One of the concerns with use of α-tocopherol (used in the overwhelming majority of randomized vitamin e trials) is that it is only 1 of 8 forms of vitamin e available from foods-the 4 tocopherols and 4 tocotrienols. Furthermore, use of α-tocopherol supplements alone tends to reduce levels of γ-tocopherol, which has been shown in laboratory studies to have a number of beneficial and possible cancer-preventive effects. The SeLeCT trial shows very clearly the decline in γ-tocopherol in the α-tocopherol group: cholesterol-adjusted γ-tocopherol levels started out at 1.43 µg/mL at baseline, but after 4 years, they had fallen to 0.80 µg/mL-nearly a 50% decline. It is hard to ignore that this decline might have adversely affected cancer risk. a 2006 review of epidemiological studies of dietary intake and plasma levels of γ-tocopherol explains some of the complications of assessing effects of γ-tocopherol. 6 In the United States, 70% of dietary vitamin e consumption is actually in the form of γ-tocopherol, whereas supplement intake is usually from α-tocopherol. This is due to the very high intake of soy and other vegetable oils in the United States, which contain high levels of γ-tocopherol. Of course, this raises a distinct problem (actually not discussed in detail in the 2006 review) because soy oil also contains high levels of the ω-6 linoleic acid, which is known to boost production of cancer-promoting prostaglandins. The protective γ-tocopherol is thus accompanied by the possibility of increased synthesis of harmful prostaglandins. Nevertheless, it is interesting to note that this review observed that the epidemiological studies suggested that γ-tocopherol had a protective effect for prostate cancer. What was the effect of lowering the γ-tocopherol with α-tocopherol supplements in the SeLeCT trial? We don't know, however, it is possible this decrease might have been a factor with the lack of reduction in cancer risk. What would the effect be antioxidants: SeLeCTed out? / Block 7 of higher levels of γ-tocopherol not accompanied by linoleic acid? We know even less. Logic would say high levels of γ-tocopherol without the large amounts of the linoleic acid from soybean oil would be helpful. It is clear that our understanding of the forms of vitamin e and their health effects has a long way to go.
Of course, the problem that is at the bottom of all the negative results of antioxidant trials that are currently being published is the pharmaceutical approach to cancer prevention that this era of natural products research represents. The take-a-pill-to-prevent-cancer approach is laudable in its desire to simplify health practices, but it is unfortunately not based on a full understanding of the biology of cancer or health in general. Recently published studies have shown us that cancers have multiple and diverse genetic mutations. Does it really make sense, then, that taking a rather small dose of an isolated single antioxidant-or two-is going to so deeply change the internal environment of the body that it can overcome continuing intake of a diet high in inflammatory and oxidizing foods? Of course not. It appears the nutrition research community is finally coming around to this viewpoint. In his editorial that accompanies the SeLeCT trial, 3 Peter gann of the Department of Pathology, University of Illinois at Chicago states, Single-agent interventions, even in combinations, may be an ineffective approach to primary prevention in averagerisk populations. It may be time to give up the idea that the protective influence of diet on prostate cancer risk-which is clearly observed in migrant studies and in populations transitioning to a Western diet-can be emulated by isolated dietary molecules . . . On the other hand, nonpharmacological dietary prevention of prostate cancer is probably more complex and may involve certain inconvenient truths . . . it may be necessary to give up the reductionist need to know which molecule is most responsible and perhaps give up the notion of placebo controls as well . . . This does not mean that whole food or complex mixture studies cannot be sound and biologically based. One can start, for example, by asking how diet affects intraprostatic androgen activity, a proven chemopreventive mechanism. I applaud gann for taking this position so publicly and would certainly advocate the use of whole foods, whole plant formulations, and complex mixture studies as a future approach to cancer prevention and also cancer treatment. This may make grant review committees uncomfortable, as studies on single molecules have much more of an aura of "good science" about them to investigators schooled in the pharmacological model of health. But the plethora of trials showing the ineffectiveness of single antioxidant supplements should certainly cause a reevaluation of the pharmacological approach to nutrition and health promotion.
To return to the question raised by the title of this commentary, whether antioxidants have been selected out of the running in the evolution of nutritional science, I must confess that the full topic is larger than I can address in this short contribution. What we have learned from the SeLeCT trial and others like it is only a small part of the science of antioxidants. I will say that I feel that antioxidants do have a continuing role to play in cancer prevention and treatment-but not in the way that these trials have explored them. antioxidant phytochemicals need to be taken in the way in which our body is accustomed to receiving them, as diverse collections of interacting chemicals. Specifically, antioxidants have "network" properties, trading around free radical effects among a diverse set of molecules to ameliorate their effects on the body as a whole. Single antioxidants are bound to be ineffective if not harmful in this model of their function. Second, antioxidants have multiple interesting and potentially useful properties that have been listed in a dizzying array of research articles. However, we now know from research on β-carotene and other compounds that taking high doses of single antioxidants in the context of a highly oxidized environment such as that of smokers can backfire, as the pro-oxidant properties of these molecules are triggered in such environments. Thus, antioxidant supplements need to be taken in the context of an improved biochemical environment to avoid the pro-oxidant triggers. I discussed an instance of this effect in the June 2008 editorial of Integrative Cancer Therapies. 7 In a study by Meyer et al 8 on use of antioxidant supplements in head and neck cancer patients undergoing radiation, it was only the current smokers, not the nonsmokers or ex-smokers who had increased mortality when they took antioxidant supplements. This implies that antioxidant supplements should be used as supplements to a healthy diet and lifestyle, and not substitutes. You cannot take a pill to counteract the effects of a poorquality, high-fat, low-phytochemical or simply, junk-food diet. Finally, the broad-spectrum multivitamin model of antioxidant supplements may actually be useful, especially in populations at nutritional risk from various causes, by helping provide basic levels of antioxidants and related compounds. Nutritional risks may include aging, dietary restrictions, and illness such as cancer. However, multivitamins should be composed of whole plant-based food extracts and complex substances, and cover the full gamut when considering select nutrients, such as mixed tocopherols or mixed carotenoids-in other words, as close to foods as possible.
Keith I. Block, MD
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